Dinara Ryspayeva

Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results.

Marina Maglakelidze, Iurie Bulat, Dinara Ryspayeva et al. · Journal of Clinical Oncology · 2021 · 26 citations

Medicine, Oncology, Pharmacology +17

Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)

Joshua Tobias, Marina Maglakelidze, Zoran Andrić et al. · Clinical Cancer Research · 2024 · 23 citations · Full text

Medicine, Immunology, Oncology +17

Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?

Dinara Ryspayeva, V. Halytskiy, Nazarii Kobyliak et al. · Discover Oncology · 2022 · 12 citations · Full text

Medicine, Molecular Medicine, Oncology +17

HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis.

Marina Maglakelidze, Dinara Ryspayeva, Zoran Andrić et al. · Journal of Clinical Oncology · 2023 · 12 citations

Medicine, Immunology, Oncology +15

Predictive factors of pathological response to neoadjuvant chemotherapy in patients with breast cancer.

Dinara Ryspayeva, Andrey Lyashenko, Irina Dosenko et al. · PubMed · 2020 · 10 citations

Medicine, Oncology, Breast Oncology +16